The anticonvulsant properties of the ß-adrenoceptor antagonist propranolol and its two enantiomers were examined in various screening tests in order to characterize the anticonvulsant profile as well as the possible molecular mechanism of action. These compounds dose-dependently raised the threshold for tonic electroshock seizures in mice and were effective in the traditional maximal electroshock test (ED 50 s 15-20 mg kg −1 i.p.). In combination with clinically used antiepileptics, the anticonvulsant effectiveness of the latter was significantly increased. In the pentylenetetrazol (85 mg kg −1 s.c.) seizure threshold test, (±)-and (+)-propranolol were not effective in preventing clonic seizures. In unrestrained rats with chronically implanted electrodes in the dorsal hippocampus, propranolol and its (+)-enantiomer equieffectively reduced the duration of electricallyevoked hippocampal afterdischarges (10 and 20 mg kg −1 i.p.) and raised the focal stimulation threshold (20 mg kg −1 i.p.). In amygdala-kindled rats, both drugs (≥10 mg kg −1 i.p.) reduced the seizure severity from stage 5 (generalized clonic-tonic) to stage 3 (unilateral forelimb) seizures. Furthermore, whole-cell patch-clamp experiments showed that (+)-as well as (−)-propranolol (10 −6 to 10 −4 M) depressed the fast inward sodium current in a concentration-and use-dependent manner in cultured rat cardiomyocytes and inhibited picrotoxin-induced burst firing activity of mouse spinal cord neurones in culture. In conclusion, propranolol and its two enantiomers have anticonvulsant effects in models for generalized tonic-clonic and complex partial seizures which may be accounted for by the sodium channel blocking and not by the ß-adrenoceptor blocking activity.
INTRODUCTION
Propranolol is a prototype, non-selective ß 1 /ß 2 -adrenoceptor antagonist, having an established indication in a variety of cardiovascular diseases including essential hypertension, cardiac arrhythmias and angina pectoris for more than 30 years 1, 2 . It is known that this lipophilic drug exhibits marked central actions, such as anxiolytic, antiaggressive and antipsychotic effects, with possible indications in neurology and psychiatry [3] [4] [5] . Interestingly, pronounced anticonvulsant properties in various seizure models were also documented (for review, see Reference 6) . Propranolol potently prevents maximal electroshock (MES) seizures in rodents and raised the after discharge threshold in rats 7, 8 . These basic observations indicate that the profile of anticonvulsant activity seems to be similar to that of phenytoin and carbamazepine, established antiepileptic drugs in the treatment of generalized tonic-clonic and partial seizures in humans. Phenytoin and carbamazepine block high-frequency repetitive firing of action potentials and sodium channels are the likely molecular targets of these antiepileptics 9, 10 . Some authors described anticonvulsant effects of propranolol against sound-induced seizures in DBA/2 mice or pentylenetetrazol (PTZ)-induced convulsions in rats, in which the (−)-enantiomer was more potent than the (+)-enantiomer 11, 12 . However, the majority of other studies in several animal models suggests that the anticonvulsant action of propranolol does not result from ß-adrenoceptor blockade 13, 14 and may be due to the 'membrane stabilizing' properties of this drug 8, 15 .
Anecdotal reports show that propranolol may be useful for treatment of seizures in humans 16, 17 . In particular, this substance might also be used in patients suffering from epilepsies associated with increased blood pressure and cardiac dysfunctions. The objective of the present work was to determine the antiepileptic profile of propranolol and the mode of ac-tion in a series of appropriate screening models. Apart from various, mostly not very extensive, studies using electroshock-and pentylenetetrazol-induced seizure tests, detailed investigations with different seizure threshold and chemoshock tests as well as complex partial seizure models like the amygdala kindling are missing (see Reference 6) . In order to clarify whether the blockade of ß-adrenoceptors is involved in the mechanism of action, experiments with (−)-and (+)-propranolol (the latter is essentially devoid of ß-adrenolytic effects but shares the membrane stabilizing properties of the (−)-enantiomer) were performed. Since propranolol may be useful as an adjunctive drug in epilepsies, the modulation of the protective efficacy of conventional antiepileptic drugs by combined treatment was also analysed. Finally, the inhibitory effects of propranolol on the fast inward sodium current, which could be inferred from previous studies, were examined in detail using whole-cell patch-clamp technique.
METHODS

Animals
In most of the screening tests (MES, PTZ, Rotarod; see later) male albino mice (strain 01, Leipzig-Probstheida, Germany), weighing 19-25 g (27-to 32-day-old) were used. Two special seizure models (maximal N-methyl-DL-aspartate (NMDLA) and quinolinate (QUIN) seizure test) were carried out on male SHR mice (bred from Swiss strain, Rappolovo farm, St Petersburg, Russia), weighing 18-22 g. (For the patch-clamp experiments on spinal cord neurones, foetal 12-to 13-day-old NMRI-Han mice (Hanover, Germany) were used.) After adaptation to laboratory conditions for some days, the experimental groups were chosen by means of a randomized schedule. Each mouse was used only for one experiment. The EEG-studies (hippocampal afterdischarges) as well as the pharmacokinetic investigations were carried out with male Wistar rats (own breeding stock, formerly 'Jelei: WIST'), weighing 250-300 g at the time of surgery. The studies with amygdala-kindled rats were performed on female Wistar rats (strain 'Shoe: WIST', Schönwalde, Germany), weighing 150-220 g at the beginning of the experiments. The animals were kept in colony cages under standard laboratory conditions on a natural light-dark cycle with free access to commercial food pellets and tap water. The screening experiments were carried out between 9 and 12 hours to avoid circadian influences. Animal care and handling was conducted in compliance with the German Animal Welfare Act and was approved by the relevant local governmental body in Leipzig.
Maximal electroshock seizure threshold (MES-T) test (mice)
The stimulus train was applied via ear-clip electrodes (sinusoidal pulses 5-10 mA, 50 Hz, 0.2 seconds duration) by means of a constant current stimulator (rodent-shocker type 221; Hugo Sachs Elektronik, March-Hugstetten, Germany). The stimulus intensity was varied by an up-and-down method in which the current was raised or lowered in 1 (or 2) nA-steps if the preceding animal did not or did show tonic hindlimb extension, respectively (see Reference 18) . Groups of 15-20 mice were used. Current intensityeffect curves were constructed on the basis of the percentage of animals responding with the endpoint at the corresponding current value. The calculation of CC 50 values (current intensity in mA, necessary to induce tonic hindlimb extension in 50% of the mice tested) and the statistical comparisons were performed using a computer-supported probit analysis according to the method of Litchfield and Wilcoxon 19 . In the case of multiple comparisons between different drug-treated and the corresponding control group, α-correction was performed.
Maximal electroshock seizure test (mice)
Maximal electroshock seizure was induced in mice via ear-clip electrodes by a constant suprathreshold current (rectangular 20 msecond impulses, 50 mA, 35 Hz, 0.4 seconds duration) following the method of Swinyard et al. 20 . The prevention of the hindlimb tonic extensor component was regarded as the endpoint of protection. The dose-response curves were estimated by testing four to five doses and eight (sometimes 10-16) animals per dose. The calculation of ED 50 values (dose that protects 50% of the animals against MES-induced tonic hindlimb extension) and the statistical analysis were performed according to the traditional method of Litchfield and Wilcoxon 19 .
Pentylenetetrazol (PTZ) seizure threshold test (mice)
In all chemically-induced seizure models the convulsants were given after the optimal pretreatment time of the test drug (or vehicle). Unrestrained mice were injected with the convulsant PTZ (85 mg kg −1 ) s.c. in the neck. The animals were placed under separate glass funnels and the appearance of the first generalized clonus (repeated clonic seizures of the fore-and hindlimbs lasting ≥5 seconds with an accompanying loss of righting reflex) was recorded during individual observation for 30 minutes (see Reference 21) . The number of animals in the group (n = 12 mice) with clonic seizures and the latency time were analysed for statistical significance using Fisher's exact probability test and the Log rank test, respectively.
Maximal pentylenetetrazol (PTZ) seizure test (mice)
Clonic-tonic convulsions were induced by administering PTZ (125 mg kg −1 ) s.c. in the neck of mice (see Reference 22) . In all chemically-induced tonic seizure models the following criteria were used for quantification of drug effects: the number of animals in the group (n = 12) with tonic hindlimb extension (1), the latency time to the first tonic seizure (2) and the survival time (3). Results were compared statistically by using Fisher's exact probability test (1) and the Log rank test (2, 3), respectively.
Maximal N-methyl-DL-aspartate (NMDLA) and quinolinate (QUIN) seizure test (mice) NMDLA (2 µg/5 µl) and QUIN (25 µg/5 µl), respectively, were injected i.c.v. in conscious mice by a semiautomatic apparatus 23 . Animals were placed in separate boxes and observed individually for 15 minutes. The doses of chemoconvulsants were chosen from our own pilot studies to induce tonic seizures and a short survival time. (It should be mentioned that in the vehicle-pretreated control groups (n = 15) normally one to three animals exhibited no tonic hindlimb extension.)
Strychnine (STR) seizure pattern test (mice)
Tonic seizures were induced by administering STR (1.4 mg kg −1 ) s.c. in the neck of mice (see Reference 24). Preliminary studies showed that 1.2 mg kg −1 did not produce a clear tonic hindlimb extension in all mice tested. As mentioned earlier, the occurrence of the first tonic seizure (hindlimb extension) and the survival time were registered after individual observation for 30 minutes. In this test, groups of nine mice were used.
Rotarod ataxia test (mice)
Sedation, decreased locomotor activity and ataxia were quantified by the rotarod test 25 . Mice were tested and trained before drug application. Evidence for 'minimal neurotoxicity' was indicated when the animals were unable to maintain their equilibrium on the rotating rod (10/minute) in two of three subsequent 1 minute attempts. Respective TD 50 values (dose in which 50% of the animals show impaired motor performance) were calculated with three to four doses (10 mice per dose) on the basis of dose-response curves using the method of Litchfield and Wilcoxon 19 .
Electrically-evoked hippocampal afterdischarges (rats)
Anaesthetized rats (ketamine-HCl 100 mg kg −1 i.p./ xylazine-HCl 15 mg kg −1 i.p.) were placed in a stereotaxic apparatus (TSE, Bad Homburg, Germany). A bipolar deep electrode for intracerebral stimulation and recording was implanted into the right dorsal hippocampus (AP 2.5 to 3.0 posterior to bregma, L = 1.8 mm lateral to the midline and V = 2.7-3.0 mm ventral to the skull surface; stereotaxic coordinates according to Fifková and Maršala 26 ). Additionally, for EEG-recording six stainless-steel electrodes were positioned epidurally above the bulbus olfactorius, the sinus sagitalis superior (reference electrode; 2 mm frontomedially to the bregma), the sensomotor and visual cortex. At the end, an antibiotic (Retacillin compositum, 200 000 IE, Jenapharm, Jena, Germany) was administered. Two weeks after surgery, the rats were habituated to the recording setup and EEGrecordings (Bioscript BST 1, Zwönitz, Germany) were performed within the following 2-3 days. Constant current stimulations were delivered to the deep electrodes in the hippocampus, when a stable EEG response has been established from the freely behaving animals. The stimulus train (rectangular 1 msecond current impulses, 60 to 300 µA, 50 Hz, 5 seconds duration) was applied from a HSE-stimulator (type 215/1, HSE, March-Hugstetten, Germany) coupled to a stimulus isolation unit and a constant current unit. The individual stimulation threshold for hippocampal rhythmic spike activity ('afterdischarges') was estimated with a series of stimulations, commencing with 60 µA and increasing in 20 µA steps every 2 minutes until an afterdischarge was elicited (for further details, see Reference 27) . Selected drugs could be studied when the duration and pattern of the hippocampal afterdischarges remaining nearly constant over three to four tests. Each animal received no more than three drug applications (controls before and after drug administration at intervals of 3-4 days; at least 6 days were interposed between two drug injections in order to avoid drug accumulation or tolerance). Statistical differences between groups of data were established by the paired Student's t-test.
Amygdala-kindling (rats)
Surgery and kindling procedures were performed as described elsewhere 28 . Briefly, rats were anaes-thetized and implanted with one bipolar electrode (stainless steel wires tightly twisted together) positioned stereotaxically into the right basolateral nucleus of amygdala (AP 1.7 mm posterior to bregma, L = 4.0 mm lateral to the midline and V = 8.0 mm ventral to the dura 26 ). Two weeks later, the animals were stimulated once daily with rectangular 1 msecond current impulses (100 to 200 µA depending on the individual threshold for afterdischarges, 60 Hz, 1 second). The animals were considered to be kindled after the achievement of at least three consecutive generalized seizures with stages 4/5. The severity of seizures was classified behaviourally according to a modified ranking scale 6, 29 : 0 = no response to stimulation; 1 = immobility, eye closure, ear and facial twitches; 2 = head nodding, more severe facial clonus, lacrimation; 3 = unilateral forelimb clonus; 4 = rearing, bilateral forelimb clonus with loss of postural control; 5 = repeated backward falling, accompanied by generalized clonic-tonic convulsions. After completion of kindling, rats were grouped to six to 12 animals and injected with saline (control values) and 1 day later with the test substance i.p. before the electrical stimulation. Results were expressed as mean (scaled pre-drug and post-drug seizure behaviour) of the tested animal group. Significance of differences was calculated using the paired Student's t-test. Electrode placements were confirmed histologically using the conventional Nissl-technique (cresyl violetstained frontal sections).
Plasma levels of phenobarbital and carbamazepine (rats)
Plasma concentrations were determined after injection of the antiepileptic drug alone (phenobarbital 10 mg kg −1 i.p., 60 minutes before or carbamazepine 10 mg kg −1 i.p., 30 minutes before; saline instead of propranolol, 45 minutes before) and in combination with propranolol (10 mg kg −1 i.p., 45 minutes before). Individual blood samples of 300-500 µl, taken from the retro-orbital venous plexus under short diethylether anaesthesia, were collected into Eppendorf tubes and centrifuged at 10 800 rev minute −1 for about 1 minute. Subsequently, 100 µl of the supernatant was pipetted into Abbott system cartridges and the total plasma level of phenobarbital or carbamazepine was determined by an Abbott TDx analyser (Abbott, Irving, TX, USA), which is based on a fluorescence polarization immunoassay (FPIA) technique. The plasma levels were expressed in µM as means ± SEM (six to 10 rats for each group). For comparison of the plasma levels of phenobarbital and carbamazepine in saline-or propranolol-treated rats, the Mann-Whitney rank sum test was used.
Heart cell culture (neonatal rats) and whole-cell voltage-clamp experiments Ventricular myocardiocytes from 1-to 3-day-old Wistar rats were prepared by using a combined enzymatic (0.2% trypsin) and mechanical dissociation procedure and cultured as monolayers on coverslips at 37 with Tris-HCl. Sodium currents from selected cardiomyocytes were studied using the whole-cell patchclamp technique 31 by means of an EPC-7 patch-clamp amplifier (List Electronics, Darmstadt, Germany). The experimental setup and the data acquisition have been described in detail elsewhere 32, 33 . The drugs tested, propranolol, its two enantiomers, valproate and phenytoin (in DMSO), were dissolved and diluted in external solution to the desired concentrations immediately before use. The drug solutions were applied with an automated application system.
Spinal cord neurone culture (neonatal mice) and picrotoxin (PTX)-induced burst activity
Spinal cord neurones from 12-to 13-day-old mice were prepared by using a combined enzymatic (0.25% trypsin) and mechanical dissociation procedure and cultured on collagen-coated plastic dishes using methods described elsewhere 34 . For the electrophysiological studies, the cultures (14 days in vitro) were placed on the stage of an inverted microscope and superfused with control (HEPES-buffered saline) or PTX-containing solution, respectively. All recordings were carried out using the whole-cell patch-clamp configuration in current-clamp mode (for further details, see References 34, 35) . When picrotoxin (10 µM) was applied to the cell culture, the neurones within the neuronal network developed paroxysmal, burst-like firing activity within 10-15 minutes. The effects of (+)-and (−)-propranolol (1-30 µM) were tested by cumulative administration to the PTXsuperfusion solution.
Drugs and solutions
The following substances were used: (±)-propranololHCl, (+)-, (−)-propranolol-HCl (purity of the enantiomers approximately 98%), N-methylpropranololHCl (Isis-Chemie, Zwickau, Germany), carbamazepine, ethosuximide, phenobarbital-Na, valproateCa (Arzneimittelwerk Dresden, Germany), phenytoinNa (Gödecke, Freiburg, Germany); N-methyl-DLaspartate (IEM, St. Petersburg, Russia), pentylenetetrazol (Knoll, Ludwigshafen, Germany), picrotoxin (Sigma, Deisenhofen, Germany), quinolinic acid (Sigma, St Louis, USA), strychnine-SO 4 (Merck, Darmstadt, Germany). The drug solutions or suspensions were prepared immediately before use. All doses refer to the salts. For the screening experiments, propranolol, its enantiomers and Nmethylpropranolol were dissolved in distilled water (phenytoin-Na by means of 1-2 drops of 1N NaOH), N-methyl-DL-aspartate (pH 7), quinolinic acid (pH 6-7), pentylenetetrazol, strychnine in 0.9% NaClsolution, carbamazepine, ethosuximide and valproateCa in a 2% suspension of hydroxyethylcellulose. Animals in the control groups received equivalent volumes of the vehicle (10 ml kg −1 in mice; 2 ml kg −1 in rats) and were always tested together with the respective experimental group.
RESULTS
Effects of (+)-and (−)-propranolol on the threshold for electroshock-induced tonic seizures
Both (+)-and (−)-propranolol (10 mg kg −1 i.p.), administered 30 minutes before testing, significantly raised the threshold for electricallyinduced tonic (hindlimb extension) seizures in mice from 5.8 mA (mean of two control groups with saline) to 7.7 and 7.4 mA, respectively ( Fig. 1 : presentation in percent to the corresponding control group). At the lower dose (2 mg kg −1 i.p.) no strong influence on the electroconvulsive threshold could be observed. In combination with phenobarbital, phenytoin, carbamazepine or valproate, the tested (+)-enantiomer significantly increased the effectiveness of the latter.
Anticonvulsant activity of (±)-, (+)-and (−)-propranolol as well as N-methylpropranolol in the maximal electroshock seizure test (±)-Propranolol and its two enantiomers showed anticonvulsant effects in the traditional MES test in mice. The animals exhibited no post-ictal depression (confusion and stupor) and quickly recovered after the induced tonic seizure. N-methylpropranolol, which does not possess ß-adrenolytic properties, exerted a similar protective action. Table 1 summarizes the estimated ED 50 values of these drugs and some conventional antiepileptics as reference substances after different routes of administration. The anticonvulsant activity of propranolol as well as its (+)-enantiomer was roughly equipotent to phenobarbital in this test. Interestingly, (−)-propranolol (the enantiomer with the marked ß-adrenoceptor blocking action), tended to have a lower anticonvulsant activity than the (+)-enantiomer. The efficacy of clinically established antiepileptics was considerably increased when (±)-or (+)-propranolol (10 mg kg −1 s.c.) were administered as co-medication. The ED 50 values were significantly reduced in all cases (Fig. 2 ). Detailed studies with phenobarbital and (±), (+)-, (−)-propranolol as well as the N-methyl-derivative showed a dose-dependent decrease of the ED 50 values (see Fig. 2 : left part of the diagram).
Influence of (±)-and (+)-propranolol on pentylenetetrazol-, N-methyl-DL-aspartate-, quinolinate-and strychnine-induced tonic seizures
As illustrated in Fig. 3 , the racemic propranolol and the (+)-enantiomer can suppress tonic (hindlimb extension) convulsions in different chemically-induced seizure models in mice. For comparison, the effects of some antiepileptics are also presented. When tonic seizures were induced by systemic administration of PTZ or central administration of NMDLA and QUIN, respectively, both drugs dose-dependently inhibited tonic convulsions (Fig. 3: upper diagram) . In the remaining animals with tonic seizures, the latency to the first tonic seizure showed a tendency to increase (not demonstrated). The survival time was significantly prolonged (lower diagram). On the other hand, in the STR seizure test (±)-and (+)-propranolol revealed only limited protective actions and, as expected, the efficacy of conventional antiepileptics was also limited.
Influence of (±)-and (+)-propranolol as well as N-methylpropranolol in the pentylenetetrazol seizure threshold test Neither (±)-and (+)-propranolol nor the N-methylderivative exerted protective effects in lower or higher doses in the s.c.-PTZ seizure threshold test in mice (Table 2) . At 20 mg kg −1 i.p. the latency to the first generalized clonus tended to decrease, indicating possible proconvulsant actions. On the other hand, the reference antiepileptics ethosuximide and valproate exhibited significant anticonvulsant effects against clonic seizures. Upper part: number of animals with tonic seizures (dotted boxes) within the groups. + P < 0.05; ++ P < 0.01; +++ P < 0.001 (Fisher's exact probability test). Lower part: Corresponding survival times (means ± SEM) as percent of the control groups. (Regarding the differences in the absolute values, depending on a short or longer survival time of the control animals in these various seizure test and the number of protected animals (calculated with censored 30 or 15 minutes, respectively) in the drug treated groups, it seems necessary to limit all data to 300% for a clear presentation.) The doses of the tested drugs are indicated below the columns. (The times of administration of the drugs before application of the chemoconvulsants were always 30 minutes for (±)-, (+)-propranolol and valproate and 60 min for phenobarbital and carbamazepine.) The average control values ± SEM were: PTZ 11.4 ± 0.8 minutes (n = 5 control groups); NMDLA 1.4 ± 0.3(n = 5); QUIN 1.5 ± 0.3(n = 4) and STR 5.7 ± 0.3(n = 5). * P < 0.05; * * P < 0.01; * * * P < 0.001 (Logrank test). All data are given as means ± SEM. Statistical significance: +++ P < 0.001 (Fisher's exact probability test); * P < 0.05, * * P < 0.01 (Logrank test). NaCl-Cellulose = 0.9% NaCl in 2% hydroxyethylcellulose suspension.
Adverse effects of (±)-and (+)-propranolol
Impairment of motor function and an increasing sedation could be observed in mice after application of higher doses (≥30 mg kg −1 i.p.) of (±)-or (+)-propranolol. 
Effects of (±)-and (+)-propranolol upon electrically-evoked hippocampal afterdischarges
In unrestrained rats stimulated by chronically implanted hippocampal electrodes, (±)-and (+)-propranolol (10 and 20 mg kg −1 i.p.) reduced or completely suppressed the initial phase of generalized polyspike-wave and spike discharges. A representative EEG-recording with (+)-propranolol is illustrated in Fig. 4 . The secondary (rebound) afterdischarge phase, characterized by sharp-waves in the hippocampus and visual cortex beginning about 80-90 seconds after the stimulation, was also suppressed. The calculated mean effects of racemic propranolol and its (+)-enantiomer on the duration of hippocampal afterdischarges (initial phase) are shown in Fig. 5(a) . The influence on the stimulation threshold to induce afterdischarges is illustrated in Fig. 5(b) . Both drugs revealed activities equalling or exceeding those of phenobarbital and phenytoin.
Further studies with (+)-propranolol (10 or 20 mg kg −1 i.p.) given in combination with phenobarbital and phenytoin, respectively, showed that this co-medication enhanced markedly the effectiveness of the two antiepileptics (Fig. 6) . The higher dose of (+)-propranolol did not only completely inhibit the afterdischarge activity, but in addition, significantly elevated the stimulation threshold.
Effects of (±)-and (+)-propranolol in the amygdala-kindling model
In amygdala-kindled rats, (±)-and (+)-propranolol exerted anticonvulsant activity against secondarily generalized clonic-tonic seizures (stage 4/5). At doses of 10 mg kg −1 i.p. both drugs reduced seizure severity to stage 3, but did not suppress the facial and unilateral forelimb cloni (Fig. 7) . The efficacy of some antiepileptics was presented for comparison.
Effects of propranolol on the plasma level of phenobarbital and carbamazepine
Propranolol (10 mg kg −1 i.p.) did not alter the total plasma levels (µM) both of phenobarbital (10 mg kg −1 i.p.) (alone 48.9 ± 1.1 Fig. 4 : Electrically-evoked epileptiform spike activity ('afterdischarges') following hippocampal current stimulation in the unrestrained rat (EEG-recording example). After habituation of the animal for 15 minutes (relaxed wakefulness) the stimulus was delivered to the right dorsal hippocampus (region 4-5). Top panel: control recording before and after stimulation (rectangular 1 msecond current impulses of 180 µA and 5 seconds duration) without drug treatment. The evoked epileptiform activity has a complex pattern which consists of (1) initial polyspike-wave and spike discharges (without convulsive response), associated with postural freezing and with some head-shakes (HS) at the end, (2) a period free of afterdischarges (post-ictal voltage depression), with pronounced forward locomotion, sniffing and rearing activity, and (3) a second (rebound) phase after 80-90 seconds characterized by sharp-waves (see hippocampus, visual cortex), with a short arrest, some head-shakes and after that again increased locomotor activity for 3 (5) minutes. Bottom panel: effect of a single dose of (+)-propranolol (10 mg kg −1 i.p.) on electrically-evoked hippocampal afterdischarges, recorded 30 minutes after drug application (3 days after predrug control). (+)-Propranolol markedly reduced the initial spike-wave phase and the second (sharp-wave) phase was completely suppressed. SMC = sensomotor cortex; DH = dorsal hippocampus; VC = visual cortex; BO = bulbus olfactorius. Voltage calibration on the right: 60 µV.
(n = 10) vs. 48.4 ± 1.5 (n = 6)) or carbamazepine (10 mg kg −1 i.p.) (alone 19.8 ± 2.4 (n = 10) vs. 18.8 ± 3.8 (n = 6)). There are no relevant pharmacokinetic interactions, in terms of total plasma levels, between propranolol and the two tested antiepileptics.
Effects of (+)-and (−)-propranolol on fast sodium inward current I Na in cultured neonatal rat cardiomyocyte cells
Current-voltage relationship of peak I Na
Sodium currents (I Na s) were evoked by a series of 25 msecond depolarization pulses (0.1-1 Hz; holding potential of −100 mV) to different depolarizing potentials. I Na s started to activate at −60 mV reaching a maximum amplitude around −20 mV, and then declined towards the reversal potential near +40 mV. The I Na s were stable over a range of 15 minutes with only minimal 'run down' effect. The currentvoltage relationship for the peak I Na before and after application of (+)-propranolol is shown in Fig. 8(a) . (The two insets on the left illustrate the pulse protocol (above) and a family of sodium currents elicited by voltage-steps after this protocol from a selected experiment (below) under control conditions and after exposure to 100 µM of the test substance.) (+)-Propranolol and the (−)-enantiomer (in the same magnitude; not documented) reduced the I Na amplitude over the entire membrane potential axis without a shift of the curve maximum or a change in the reversal potential (decrease of the maximum I Na amplitude by about 30% (10 µM) and 50-60% (100 µM)). The onset of inhibition produced by (+)-or (−)-propranolol occurred within 3 minutes, and the block was reversible within 5 minutes of washout in drug-free extracellular solution.
Frequency-dependent inhibition of peak I Na
Under control conditions, repetitive depolarizing test pulses (25 mseconds; from −120 mV to −30 mV) produced little decrement in current amplitude (2-3% at 10 Hz in a train of 10 test pulses). After application of (+)-and (−)-propranolol, respectively, the drugs led to a 'tonic' reduction of peak I Na measured after 3-5 minutes with some single test pulses. An increase of the test pulse frequency to 1 or 10 Hz, markedly increased the amount of current block by both (+)-and (−)-propranolol ( Fig. 8(b) ). At 1 Hz, the peak I Na decreased about 30% with 100 µM (+)-or (−)-propranolol and at 10 Hz up to 80%. Thus, both enantiomers exhibited a pronounced frequencydependent inhibition of peak I Na , especially at higher drug concentrations. These additional blocking effects always recovered after the reduction or cessation of higher frequency stimulation.
Steady-state inactivation of peak I Na
The voltage-dependence of I Na block was estimated by applying a conditioning 200 msecond prepulse * P < 0.05; * * P < 0.01; * * * P < 0.001 (paired t-test).
(varying from −120 mV to different depolarizing potentials up to −10 mV in increasing 10 mV steps) to the cell followed immediately by the 15 msecond test pulse (from −120 to −30 mV). Both enantiomers shifted the voltage-dependence of steady-state inactivation in a more hyperpolarized direction without marked change in the slope of the curves. Figure 8(c) shows the relationship between the steady-state inactivation and the membrane potential before and after exposure to (+)-propranolol from two representative experiments. Under control conditions, sodium currents began to inactivate at prepulse potentials positive to about −90 mV and steadystate inactivation was complete at about −50 mV. Significance level: * P < 0.05; * * P < 0.01; * * * P < 0.001 (paired t-test). as (−)-propranolol decreased to the same extent the potential-dependent availability of sodium channels, i.e. the number of channels for opening at the resting potential.
Concentration-dependent inhibition of peak I Na
The concentration-dependent inhibition of peak I Na by (+)-and (−)-propranolol in comparison with phenytoin and valproate is shown in Fig. 9 . The concentration-response curves were obtained by cumulative administration of drugs up to 10 µM; before application of 100 µM, a washout period was generally inserted to reduce long-lasting drug influences and irreversible effects. The solid curves represent the 'tonic' inhibition 3-5 minutes after drug application (single depolarizing test pulses from −120 to −30 mV). The dashed curves indicate the additional, frequency-dependent reduction after the last of 10 pulses with 10 Hz stimulation. A clear reduction of peak I Na is already observed at 1 µM to 10 µM. Half-maximal inhibition (IC 50 ) values were in the range of 100 µM for both enantiomers. Compared to (+)-or (−)-propranolol, the inhibitory activity of phenytoin (IC 50 90 µM) was only somewhat higher. In contrast, valproate exhibited a smaller reduction of peak I Na , even at high concentrations (about 15% at 1 mM). The frequency-dependence was also not very pronounced.
Effects of (+)-and (−)-propranolol on picrotoxin-induced burst activity in cultured neonatal mouse spinal cord neurones
After application of 10 µM PTX, spinal cord neurones in culture developed a paroxysmal burst-like firing activity (Fig. 10) . The (+)-and (−)-enantiomers of propranolol were nearly equieffective in inhibiting this burst activity (concentration range 1, 10, 30 µM: 21.4/18.7, 45.1/42.6, 100/100% reduction of burst duration, respectively; n = 4 cells). The results of a representative experiment with (+)-propranolol are shown in Fig. 10 . The ß-blocker talinolol (100 µM), without marked local anaesthetic properties, exhibited no clear inhibitory influence (100 µM: 10% reduction of burst duration; n = 2 cells) (not shown).
DISCUSSION AND CONCLUSION
The aims of the present study were to determine (i) the anticonvulsant profile of propranolol and (ii) its mechanism of action. The data show that propranolol including its (+)-enantiomer with practically negligible ß-blocking activity but similar lipophilic and local anaesthetic properties 36 , exhibits anticonvulsant properties in screening models for generalized tonic-clonic seizures like the MES threshold test, the traditional MES test as well as the maximal PTZ, NMDLA and QUIN seizure test. Furthermore, in the hippocampal Fig. 8(b) : Frequency-dependent inhibition of peak I Na by (+)-propranolol (upper panels) and (−)-propranolol (lower panels) at concentrations of 1-100 µM, respectively. Means ± SEM of four to seven rat myocardial cells. Voltage-clamp pulses from −120 to −30 mV of 25 msecond duration were applied at 1 and 10 Hz, respectively, in trains of 10 impulses. The peak current amplitude for each pulse (I n ) in the train was normalized to the current amplitude elicited by the first pulse (I st ) and plotted as a function of the pulse number. The insets on the left (top diagram) show the pulse protocol and a family of I Na curves from a representative cell before (control) and after 3-5 minutes exposure to 10 µM (+)-propranolol, stimulated with 10 Hz (note the marked reduction of peak I Na pulse by pulse).
afterdischarge model, predictive for complex partial seizures (see Reference 33), (±)-and (+)-propranolol reduced the duration of afterdischarges and increased the afterdischarge threshold. It should be mentioned that in agreement with the results in both MES tests, the co-medication of (+)-propranolol markedly increased the effectiveness of the tested standard antiepileptics. Previous investigations revealed additive anticonvulsant effects of (+)-propranolol in combination with phenobarbital 37 . In fully kindled rats, (±)-and (+)-propranolol reduced the seizure severity down to stage 3 (unilateral forelimb seizures) comparable to the effects of carbamazepine, whilst phenobarbital and valproate reduced the seizure severity up to stage 1 (facial twitches). On the other hand, in the s.c.-PTZ (85 mg kg −1 ) seizure threshold test, used as the standard model for myoclonic (and absence) seizures (see Reference 38), propranolol did not exhibit protective effects against generalized clonic convulsions. Altogether, the profile of action of propranolol seems to be comparable to that of the two standard antiepileptics phenytoin and carbamazepine.
It is now well accepted that propranolol possesses anticonvulsant activity in various seizure models, although conflicting results exist in the literature regarding the effectiveness in diverse seizure tests. Surprisingly, there are no detailed studies on kindling models of epilepsy in the literature. Only Gellman et al. 39 reported that propranolol (2.5 mg kg −1 i.p.) did not alter the seizure response in fully amygdala-kindled rats. The majority of studies documented efficacy in electroshock seizure tests like the MES and/or PTZ-induced tonic seizure tests 7, [13] [14] [15] [40] [41] [42] [43] [44] [45] . As in some papers, the (+)-enantiomer is an equally or more potent drug in this relationship, suggesting that the anticonvulsant effects are not related to ß-adrenoceptor blockade 7, 14 but rather due to the 'membrane stabilizing' properties 8, 15, 46 . There are, however, two remarkable exceptions. In DBA/2 mice, a genetically sensitive strain for sound-induced generalized tonic-clonic seizures 47 , a stronger anticonvulsant potency for the (−)-enantiomer was observed (see References 11, 48;  De Sarro et al., Eur. J. Pharmacol, 2002, in press). Because of the high doses required, these authors suggested that the 'membrane stabilizing' effects in this model also markedly contribute to the anticonvulsant activity. Differences in the pharmacokinetic properties of the enantiomers or an increase in the ß-adrenoceptor density of DBA/2-mice may be responsible for the different anticonvulsant potency of (−)-and (+)-propranolol 48 . Furthermore, Louis et al. 12 and Papanicolaou et al. 49 reported that the (−)-enantiomer of propranolol was seven times more effective than the (+)-enantiomer (oral administration of 0.05-1 mg kg −1 ) in decreasing the seizure duration in PTZ(50 mg kg −1 i.p.)-induced tonic-clonic seizures in rats. They suggested that propranolol exert an anticonvulsant effect through central ß-adrenoceptors, whereas at higher dose levels, additional anticonvulsant activity is associated with membrane stabilization.
As already discussed, the virtually identical anticonvulsant potency of the non-receptor-active (+)-enantiomer and the anticonvulsant activity of N-methylpropranolol without marked ß-blocking action 50 , argue against a relevant involvement of central ß-adrenoceptors in the anticonvulsant effectiveness of propranolol.
The following arguments also speak for this statement.
1. The doses of propranolol causing anticonvulsant effects (10-20 mg range) are about 10-fold higher than those required for adequate ß-adrenoceptor blockade (1-2 mg range). 2. Pindolol and timolol, two lipophilic ß-blockers with stronger ß-adrenolytic potency than propranolol 51, 52 , exhibited a smaller or no anticonvulsant effect, respectively. 3. A subchronic pre-medication with combinations of desipramine/phenoxybenzamine or desipramine/yohimbine, which induced a rapid decrease in rat brain ß-receptor binding 53 , revealed no significant modulation of the anticonvulsant effectiveness of propranolol (data not shown, see Reference 6). Phenytoin and carbamazepine as well as a number of promising new compounds block voltage-sensitive sodium channels in a complex voltage-and frequencydependent manner 10, [54] [55] [56] . Since propranolol exhibits anticonvulsant activity in the same screening models as phenytoin and carbamazepine, it was of interest to investigate directly the possible influence of (+)-and (−)-propranolol on the fast inward sodium current I Na . In earlier studies, Tarr et al. 57 found inhibitory effects of propranolol on the fast inward sodium channel in frog atrial muscle fibres using the sucrose-gap voltageclamp technique. Further investigations showed that this drug decreased the maximum upstroke velocity (V max ) and amplitude of the action potential in heart muscle fibres [58] [59] [60] and inhibited (veratridinestimulated) Na + influx as well as batrachotoxinin binding in various brain membrane or cardiac tissue preparations in the low µM-range, indicating Na + channel blocking effects at the neurotoxin binding site 2 [61] [62] [63] . The present whole-cell patch-clamp experiments were conducted primarily with cardiomyocytes (see also Reference 27) . Although sodium channels in cardiac and nerve membranes are not fully identical, sodium channels in the heart behave functionally very much like those of neuronal cells 64, 65 . Interestingly, the expression of cardiac sodium channel mRNA was recently demonstrated in restricted areas of rat and human brain, especially in limbic structures and diencephalon 66, 67 . Hartmann et al. 66 suggested that 'arrhythmias' of heart and sensible brain regions may be related and implicate these tetrodotoxinresistant sodium channels in some forms of primary inherited epilepsy. The present studies demonstrate that the two enantiomers of propranolol exhibit equieffective sodium channel blocking effects and the potency is very similar to that of phenytoin (10-100 µM reduced the peak I Na by approximately 20-50%). Moreover, for both propranolol enantiomers and phenytoin (see Reference 6), a clear voltageand frequency-dependence in blocking voltage-gated sodium channels were observed. These phenomena (decrease of the channel availability at stronger membrane depolarizations, increase of channel inhibition during higher stimulation frequency) may be very important mechanisms in reducing the ability of cells to fire trains of action potentials at high frequency. The present findings are in agreement with previous reports on the complex interactions of phenytoin and carbamazepine with sodium channels 9, 55 . Together, these specific effects provide a good explanation for how such drugs can reduce neuronal hyperexcitability and suppress seizures by selectively inhibiting sustained high-frequency firing in epileptic foci without altering normal neuronal brain function 10, 68, 69 .
In addition, the whole-cell patch-clamp studies on mouse spinal cord neurones in culture showed that both (+)-and (−)-propranolol equieffectively inhibited PTX-induced paroxysmal burst-like firing activity in a concentration-dependent manner. The potency of phenytoin and carbamazepine was in the same order as determined by Binscheck et al. 35 . These authors suggested that in this model for rapid firing of action potentials within a neuronal network, the burst duration might especially be a sensitive parameter allowing quantification of anticonvulsant drug effects. On the other hand, the peripheral ß-blocker talinolol, without marked local anaesthetic properties 70 , showed no clear inhibitory effects. Also these results underline that the anticonvulsant activity of propranolol seems to be related to the known local anaesthetic properties and not to the antagonism of ß-adrenoceptors in the CNS. Further studies must show if interferences of propranolol with Ca 2+ channels 71, 72 may play a role. One might argue that the concentrations of propranolol necessary to block Na + channels are very high. However, propranolol is concentrated in the brain of animals and man. A single dose of (±)-propranolol (22 mg kg −1 s.c.; mice), causes a brain concentration of 20.3 µg g −1 (8×10 −5 M; brain-plasma relationship 26 : 1) 73 . In humans (usual therapeutic dose range 80-320 mg day −1 ) 74 , propranolol (80 mg p.o. twice daily) causes brain concentrations of 0.8-5.7 µg g −1 (0.3-2 × 10 −5 M; brain-plasma relationship 17 : 1) 75 . Moreover, in the treatment of therapy-resistant schizophrenic patients excessive propranolol doses (means of 500-1600 mg day −1 ) were used 5, 76 .
The anticonvulsant effects of propranolol were observed in a dose range in which approximately 10-20% reduction in heart rate (unrestrained rats) and 5-20% decrease in mean arterial blood pressure (urethan-anaesthetized rats) was determined after (−)-propranolol (10-20 mg kg −1 i.p., 30 minutes after application) (for further details, see Reference 77) . The haemodynamic effects of the (+)-enantiomer at higher doses were only somewhat smaller. In another study with a lower dose of (±)-propranolol (5 mg kg −1 i.p., daily for 10 days), Pessina et al. 78 reported no significant influence on the systolic and diastolic blood pressure in normotensive as well as spontaneously hypertensive rats and only a significant reduction in heart rate in the latter. The possibility that the changes of cardiovascular parameters can be of relevance for the anticonvulsant properties of propranolol, however, seems to be very unlikely. For example, various potent peripheral ß-adrenoceptor antagonists like bisoprolol, bunitrolol, talinolol and timolol, which can be assumed to produce similar patterns of haemodynamic effects in adequate doses, revealed no anticonvulsant properties in the MES test 6 .
To the knowledge of the author, there exist no controlled clinical studies of antiepileptic effects of propranolol. However, some findings in the literature provide evidence for beneficial therapeutic effects by the additive administration of this drug. For example, in a case report of a young woman with complex partial seizures following head trauma, the combination of carbamazepine and propranolol (120 mg twice daily) seems to produce synergistic antiepileptic effects 16 . In the treatment of startle epilepsy, a rare but severe seizure disorder with predominantly tonic and tonic-myoclonic seizures, propranolol (up to 240 mg day −1 ) was reported to be an additional and safe drug 17 . Furthermore, propranolol has been used effectively for the treatment of valproate-induced tremor and relevant drug interactions were excluded 79, 80 . Concerning the fact that complex partial seizures are frequently associated with an increase in blood pressure and cardiac dysfunctions 81, 82 and ictal heart arrhythmias seem to be an important risk factor of epilepsy 83, 84 , the co-medication of propranolol or its (+)-enantiomer with pronounced cardioprotective effects 85 might be of interest. Principally, an investigation of seizure incidence in epileptic patients taking ß-blockers like propranolol for other indications should also be of importance. In addition, as suggested by Nutt 86 , propranolol may have clinical value in patients experiencing post-ictal phenomena like confusion and stupor.
Taken together, the present results show marked anticonvulsant properties of the lipophilic ß-adrenoceptor antagonist propranolol and its two enantiomers in experimental models of generalized tonic-clonic and complex partial seizures. Moreover, in combination with conventional antiepileptic drugs, additive anticonvulsant effects can be observed. With regard to the possible mode of action, these compounds were found to depress the I Na in cultured rat cardiomyocytes in a concentration-and usedependent manner and inhibited picrotoxin-induced burst firing activity of mouse spinal cord neurones in culture. It can be suggested that the sodium channel blocking properties and not the ß-receptor antagonistic activity accounts for the anticonvulsant effects of propranolol.
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